石藥(01093.HK)續跌逾4%曾創半年低 首三季多賺25%惟大和維持「沽售」評級
石藥集團(01093.HK)首三季多賺25%,大和指石藥第三季業績符合預期,但考慮到未來盈利增長放緩,維持「沽售」評級。該股三連跌,今天失守本月初所創低位,曾挫6.5%低見7.61元,創近半年低,現造7.78元,續跌4.4%,暫為最傷藍籌,成交增至1.2億股,為逾兩個半月高,涉資9.36億元。
石藥昨午公布,今年首三季純利按年增長25%至35.18億元人民幣,總營收按年升近15%至192.15億元人幣。大和指,石藥第三季業績符合預期;公司首三季核心盈利按年增長18%至33億人民幣,佔該行全年預測78%,總營收也佔該行全年預測72%。此外,市場預計石藥未來三年盈利分別增長15%、19%及21%。不過,考慮到治療中風的恩必普(NBP)專利將於2022年到期及其創新渠道薄弱,料石藥盈利增長將於2023年放緩至3%,2024年甚至可能轉降2%,故維持該股「沽售」評級目標價7元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.